Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Open Access
- 31 August 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2) , e001033
Abstract
Background: Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking. Patients and methods: We performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated outside clinical trials from eight centers in North America, Europe and Asia. Results: Patients received nivolumab for Barcelona Clinic Liver Cancer stage C (n=191, 92.0%) and Child-Pugh (CP) A (n=158, 67.8%) or B (n=75, 32.2%) HCC as first (n=85, 36.5%) or second to fourth systemic therapy line (n=148, 63.5%). Objective response rate (ORR) was 22.4% and disease control rate was 52.1%. Median overall survival (OS) was 12.2 months (95% CI 8.4 to 16.0) and median progression-free survival was 10.1 months (95% CI 6.1 to 14.2). Treatment-related adverse events of grade >2 occurred in 26 patients (11.2%). Efficacy and safety were similar across CP classes and therapy line. OS was shorter in CP-B than A (7.3 months vs 16.3 months, p=0.05). Achievement of an objective response predicted for improved OS (25.4 months vs 13.2 months, p<0.001). Conclusions: This study confirms safety and efficacy of nivolumab in advanced HCC across various lines of therapy and degrees of liver dysfunction. Despite equal ORR and toxicity to nivolumab, patients with CP-B functional class have shorter survival than the patients with CP-A.Keywords
Funding Information
- Wellcome Trust (PS3416)
This publication has 36 references indexed in Scilit:
- Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatmentHepatobiliary & Pancreatic Diseases International, 2016
- Combination cancer immunotherapies tailored to the tumour microenvironmentNature Reviews Clinical Oncology, 2015
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approachesGut, 2015
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevanceJournal of Hepatology, 2014
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directionsHepatology, 2014
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnnals of Oncology, 2012
- PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patientsInternational Journal of Cancer, 2010
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- Molecular targeted therapy for hepatocellular carcinomaJournal of Gastroenterology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008